Rockwell Medical Inc

Rockwell Medical reported second quarter 2026 results driven by new customer acquisition in the Western U.S., increased volume from existing accounts, and disciplined pricing actions. Gross margin expanded to 18% due to improved operating efficiency and the activation of two new automated liquid production lines. The company reiterated its goal of achieving approximately 30% gross margins and over $100 million in annual net sales by 2029. Management confirmed the recent reverse stock split was a strategic move to regain Nasdaq compliance and attract institutional investors, and stated it will not be followed by a capital raise. The second quarter marked a return to positive operating cash flow of $2.1 million, including final payments for the Evoqua acquisition.

Rockwell Medical has appointed Brian Cox as Vice President, Quality and Regulatory Compliance. Cox brings more than 20 years of healthcare experience from senior roles at Abbott and Johnson & Johnson, as well as growth-oriented medical device manufacturers. His expertise spans quality systems, regulatory readiness, and program management across Class I, II, and III medical devices. President and CEO Mark Strobeck said the hire supports the company's investment in compliance and quality systems as it pursues growth in the renal care market. Cox holds advanced degrees from George Washington University and the University of Texas at Arlington and is a certified Project Management Professional.